IceCure Medical Ltd. Annual Report

IceCure Medical Ltd. stands at a pivotal moment, and this report dives into their 2025 performance and strategic direction, as detailed in their SEC 20-F filing. We'll explore their groundbreaking technology, key achievements, financial health, and the critical risks and opportunities shaping their future.

Company Overview: Pioneering Cryoablation Technology

IceCure Medical Ltd., an Israel-based medical device company, specializes in cryoablation. This minimally invasive technique uses extreme cold (liquid nitrogen) to freeze and destroy tumors, offering a less invasive alternative to traditional surgery for various tumor types. The company's flagship product, the ProSense system, has secured regulatory approvals for diverse indications worldwide.

Key Milestones and Product Pipeline

Fiscal year 2025 proved pivotal for IceCure, marked by significant advancements:

• Groundbreaking FDA Marketing Authorization for ProSense: On October 3, 2025, the U.S. Food and Drug Administration (FDA) granted marketing authorization for IceCure's flagship ProSense system. This groundbreaking approval allows ProSense to treat low-risk breast cancer in women aged 70 and older who are poor surgical candidates and receiving hormone therapy. This landmark decision positions ProSense as a significant treatment option in the U.S. market for this specific patient group.
  • "Special Controls" Explained: This authorization includes "special controls," which require IceCure to conduct post-market surveillance. This involves establishing a patient registry to monitor long-term outcomes, device performance, and potential adverse events, ensuring continuous safety and efficacy data collection.
• Broader ProSense Approvals: Beyond this specific breast cancer indication, ProSense also holds broader regulatory approvals, such as FDA 510(k) clearances and the CE Mark in Europe. These allow it to treat tumors in other organs, including the lungs, kidneys, and bones, across various international markets.
• Next-Generation Systems: IceCure is also developing next-generation systems:
  • XSense System: This system, designed for enhanced efficiency and user-friendliness, received initial FDA 510(k) clearance. IceCure expects to commercialize XSense in late 2026, aiming to expand its application and streamline procedures.
  • MSense System: Currently in research and development, MSense aims to address larger or multiple tumors simultaneously, representing a future expansion of IceCure's cryoablation capabilities.
• Global Reach: IceCure's cryoablation systems have secured regulatory approvals for various tumor indications in 27 countries. This broad international footprint includes major markets like the U.S., Europe, India, Brazil, and China.

Financial Performance

IceCure Medical's shares trade on The Nasdaq Capital Market under the ticker symbol ICCM. As of December 31, 2025, approximately 73.1 million ordinary shares were outstanding.

• Revenue and Profitability: For fiscal year 2025, the company reported $2.5 million in revenue, primarily from product sales and clinical support. As an early-stage medical device company with a limited operating history, IceCure continues to incur significant operating losses, reporting a net loss of $20 million for the year. Management expects these losses to continue as it invests in commercialization and R&D.

Management's Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the company's strategic transition from a development-stage to a commercial-stage entity, driven by the landmark FDA authorization for ProSense.

• Results of Operations: The $2.5 million in revenue for 2025 reflects initial commercialization efforts and ongoing clinical support. The significant $20 million net loss primarily stems from increased investments in research and development for next-generation systems (XSense, MSense), expansion of commercial infrastructure, and regulatory compliance costs related to the FDA authorization and post-market surveillance. General and administrative expenses also rose due to public company costs and preparations for broader market penetration.
• Liquidity and Capital Resources: Management emphasizes the critical need for additional capital to sustain operations and execute its commercialization strategy. The current cash position and burn rate suggest a limited runway, requiring a substantial capital raise.
• Critical Accounting Policies: IceCure prepares its financial statements in accordance with IFRS. Key accounting policies include revenue recognition, especially for product sales and clinical services, and the capitalization of development costs—crucial given the company's R&D focus.

Financial Health

• Cash Position and Funding Needs: IceCure ended the fiscal year with $15 million in cash and cash equivalents. With an average quarterly cash burn of approximately $5 million, this provides an estimated cash runway of about 9 months. The company explicitly states it needs to raise a substantial amount of additional capital, estimated at $30-50 million, to fund operations, expand commercialization, and continue product development.
• "Going Concern" Warning: Both management and independent auditors have issued a "going concern" warning. This means that without securing additional financing, substantial doubt exists about the company's ability to continue operating beyond the next 12 months. For investors, this implies a high risk of significant shareholder dilution from future equity offerings or, in a worst-case scenario, the inability to fund operations, potentially leading to bankruptcy.

Future Outlook

IceCure's strategic focus and future outlook center on leveraging its recent FDA approval and expanding market penetration:

• U.S. Market Penetration: Following FDA authorization, IceCure plans to significantly expand its U.S. sales force, invest in physician training programs, and develop targeted marketing campaigns to drive ProSense adoption for breast cancer.
• Distribution Network: The company primarily relies on a network of third-party distributors in international markets, while building a direct sales presence in key U.S. regions. IceCure aims to strengthen existing partnerships and forge new ones to broaden its global reach.
• Clinical Evidence Generation: IceCure commits to generating robust clinical data through ongoing studies. This data will support broader indications for ProSense and demonstrate long-term efficacy and safety, crucial for physician adoption and reimbursement.
• Reimbursement Strategy: A key focus involves securing favorable reimbursement coverage from private and public payers in the U.S. and other markets. This entails working with medical societies and payers to establish CPT codes and appropriate reimbursement rates for cryoablation procedures.
• Product Development: Continued investment in the XSense and MSense systems aims to enhance the product portfolio, improve user experience, and address a wider range of tumor types and sizes.

Competitive Position

IceCure operates within the highly competitive medical device market, specifically in oncology treatments. Several factors define its competitive position:

• Proprietary Technology: The ProSense system uses unique liquid nitrogen-based cryoablation technology. IceCure positions this as a minimally invasive, precise, and effective alternative to traditional surgery, radiation, and chemotherapy for certain tumor types.
• Regulatory Milestones: The recent FDA marketing authorization for breast cancer gives IceCure a significant competitive advantage in the U.S. market for this specific indication. This differentiates ProSense from other ablation technologies that may lack such specific approval.
• Clinical Data: IceCure actively builds a body of clinical evidence, including long-term follow-up data, to support ProSense's efficacy and safety. This is crucial for physician adoption and market differentiation.
• Market Niche: By focusing on specific indications, such as low-risk breast cancer in older women who are poor surgical candidates, IceCure aims to carve out a distinct market niche where its technology offers a compelling value proposition.
• Competition: Despite its advantages, IceCure faces intense competition. Established surgical oncology procedures, radiation therapy, chemotherapy, and other ablation technologies (e.g., radiofrequency ablation, microwave ablation) compete for market share. Larger, well-capitalized companies like Medtronic and Johnson & Johnson, along with smaller specialized firms, often boast broader product portfolios, larger sales forces, and deeper financial resources.

Key Risks for Investors

Investing in IceCure Medical involves several significant risks:

• Liquidity and Funding Risk: The most critical risk is IceCure's reliance on future capital raises. Failure to secure additional financing on favorable terms, or at all, could severely impede operations, product development, and commercialization efforts, potentially leading to insolvency and significant shareholder dilution.
• Market Adoption and Commercialization Risk: Despite FDA approval, widespread adoption of ProSense for breast cancer and other indications is not guaranteed. Physician acceptance, competitive alternatives, and the pace of reimbursement coverage will dictate sales success.
• Intense Competition: The medical device market is highly competitive. IceCure faces competition from established surgical oncology procedures, radiation therapy, chemotherapy, and other ablation technologies (e.g., radiofrequency ablation, microwave ablation). Larger, well-capitalized companies like Medtronic, Johnson & Johnson, and smaller specialized firms often offer these alternatives.
• Reimbursement Uncertainty: The availability and adequacy of insurance reimbursement for cryoablation procedures are crucial for market uptake. Delays or insufficient coverage could significantly limit patient access and physician adoption.
• Supply Chain Vulnerabilities: IceCure relies on a limited number of third-party suppliers for critical ProSense system components. Supply chain disruptions could lead to manufacturing delays, increased costs, and an inability to meet demand.
• Regulatory Hurdles: Obtaining new regulatory approvals or expanding existing indications (e.g., for different types or stages of breast cancer) is a lengthy, expensive, and uncertain process. Any setbacks could delay market expansion.
• Clinical Data Generation: Continued investment in clinical trials is necessary to expand indications and drive adoption. Failure to generate compelling long-term data could hinder market acceptance.
• Talent Acquisition and Retention: As a relatively small company, IceCure's ability to scale operations depends on attracting and retaining skilled personnel, particularly in sales, marketing, and R&D. This can be challenging in a competitive labor market.

Conclusion

IceCure Medical Ltd. stands at a critical juncture. It has achieved a significant regulatory milestone with FDA marketing authorization for ProSense in breast cancer, positioning it with promising, minimally invasive technology. However, the company faces substantial financial challenges, including ongoing operating losses and an urgent need for additional capital, highlighted by a "going concern" warning. Investors should carefully weigh the potential for significant growth from its innovative technology against the high financial and commercialization risks inherent in an early-stage medical device company.